Polycystic ovarian disease

Smith, Keith D.; Steinberger, Emil; Perloff, William H.

doi:10.1016/0002-9378(65)90161-4

Cited by 69 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The correlation found between fol licle number and capsular thickness might be a matter of age. On the other hand, a connec tion between capsular thickness and high concentration of androgens has been shown [ 14,15], although such a correlation has also been denied [16]. No hormone evaluation has been taken into consideration in this study; consequently, no conclusion can be made on this issue.…”

Section: Discussionmentioning

confidence: 58%

Ovarian Morphology in Patients with Polycystic Ovaries and in an Age-Matched Reference Material

Lunde¹,

Hoel²,

Sandvik³

1988

Gynecol Obstet Invest

View full text Add to dashboard Cite

The ovarian morphology in 149 patients with the clinical syndrome of polycystic ovaries (group I) is described. The ovaries from 10 age-matched women (group II) with no signs of ovarian disorder were investigated as a reference material. The number of cysts documented for group I was twice that of the reference group and the ovarian volume three times that of the normals. No significant difference in follicle number was seen between the two groups. The tunica albuginea was thicker in group I with more pronounced atretic changes. The duration of symptoms for group I correlated significantly with body mass index, thickening of tunica, degree of stromal hyperplasia and the calculated means of ovarian volume. A correlation was also seen between ovarian volume, degree of follicular atresia and stromal hyperplasia, as well as between the thickness of the tunica albuginea, number of follicles and degree of follicular atresia.

show abstract

Section: Discussionmentioning

confidence: 58%

Ovarian Morphology in Patients with Polycystic Ovaries and in an Age-Matched Reference Material

Lunde¹,

Hoel²,

Sandvik³

1988

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Adolescent and adult female patients with virilizing CAH, before they have received glucocorticoid treatment, may have ovarian histologies similar to those in patients with polycystic ovaries (23). Treatment with glycocorticoids is followed by the return of cyclic menses (24) in some patients with the polycystic ovary syndrome.…”

mentioning

confidence: 97%

The Effect of Long Acting Glucocorticoids on Menstrual Abnormalities in Patients with Virilizing Congenital Adrenal Hyperplasia*

Richards

Grumbach

Kaplan

et al. 1978

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

Amenorrhea or oligomenorrhea occurs in more than 25% of young women with virilizing congenital adrenal hyperplasia due to 21-hydroxylase deficiency who are treated with conventional glucocorticoid therapy. In four such patients, we studied the variation in plasma concentration of ACTH, 17-hydroxyprogesterone (17-OHP), estradiol (E2), estrone, testosterone (T), dehydroepiandrosterone and its sulfate, androstenedione, and progesterone before and at frequent intervals after the administration of the patients' usual dose of oral glucocorticoids. We found that plasma ACTH, 17-OHP, and T were usually increased above the normal range early in the morning before the first daily dose of medication; plasma dehydroepiandrosterone and its sulfate were decreased below the normal range for the patient's pubertal stage; and androstenedione, estrone, and E2 were within the normal range. Two of the four patients had low basal plasma LH and impaired LH response to LRF. Administration of a long acting glucocorticoid (dexamethasone) to three patients, and methylprednisolone to one, resulted in continuous suppression of T into the normal range in all patients, in spite of continued abnormally increased concentration of ACTH and 17-OHP in two patients. In three patients, E2 concentrations were increased when a long acting glucocorticoid was given. In all four patients, menses began or became more regular during treatment with the long acting glucocorticoid. We conclude that a long acting glucocorticoid is useful in the management of menstrual abnormalities in adolescent patients with congenital adrenal hyperplasia who have attained their adult height, and that monitoring the concentration of serum T in them is a valuable but not infallible procedure for assessing the effectiveness of therapy.

show abstract

“…Although "polycystic ovaries" has become the "catch word" to describe hyperandrogenic patients with high LH and low to low normal FSH levels, the disorder is now appreciated to have a wide expres-sion of signs that include obesity, hirsutism, infertility, and amenorrhea, 4,5 all or some of which can occur in the absence of enlarged polycystic ovaries. 6 In addition, patients with other androgenic endocrine conditions, such as congenital virilizing adrenal hyperplasia, 7 androgen-producing tumors of the adrenal gland, 8 and female to male transsexuals receiving exogenous androgens, can also have polycystic ovaries. 9 Polycystic ovaries are now appreciated to be a clinical sign rather than a diagnosis.…”

mentioning

confidence: 99%